Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

Benoist Chibaudel*, Julie Henriques, Manel Rakez, Baruch Brenner, Tae Won Kim, Mercedes Martinez-Villacampa, Javier Gallego-Plazas, Andres Cervantes, Katharine Shim, Derek Jonker, Veronique Guerin-Meyer, Laurent Mineur, Chiara Banzi, Alice Dewdney, Thitiya Dejthevaporn, Haiko J. Bloemendal, Arnaud Roth, Markus Moehler, Enrique Aranda, Eric Van CutsemJosep Tabernero, Hans Joachim Schmoll, Paulo M. Hoff, Thierry André, Aimery De Gramont

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology